Testing for Mental Illness
The GeneSight Psychotropic Test analyzes how your genes affect your response to psychotropic medications commonly prescribed to treat depression, anxiety, bipolar disorder, posttraumatic stress disorder (PTSD), obsessive compulsive disorder, schizophrenia and other behavioral health conditions. There are dozens of medications used to treat depression and other mental illnesses and selecting the right antidepressant medication or other medication can be a challenging and frustrating process. GeneSight Psychotropic’s genetic testing enables your clinician to identify and avoid depression, anxiety and/or other medications that are unlikely to work or may cause side effects.
The Genecept Assay® is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect, or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes, selected based on hundreds of studies showing that variations in these genes can inform treatment decisions.
Genecept is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, attention deficit hyperactivity disorder (ADHD) and more.
Genecept has been shown in peer reviewed published studies to improve patient outcomes and reduce overall medical costs. Each test provides clinicians with an easy to read patient report and a complimentary psychopharmacogenomic consultation.
The ColorGenomics system requires a saliva sample, from which the company can look for mutations in the breast cancer genes BRCA1 and BRCA2, as well as 28 other genes for breast, prostate, colon, uterine, stomach, melanoma, pancreatic, and ovarian cancers.
Color’s test will also look at two genes, CYP2D6 and CYP2C19, that the company says impact metabolism of 13 medications for mental health. Among the antidepressants it will report on are Zoloft, Paxil, and Lexapro.
Results are reviewed by a pathologist, board certified geneticist, and two variant scientists to determine whether or not specific gene variations are pathogenic, unknown, or non-pathogenic. Clients can opt into additional experimental screening for their unknown variants through partner academic laboratories. Genetic counseling is also available after the samples have been tested. Tests are not delivered directly to the consumer, and must be ordered through a physician—either a family physician, specialist, or via the independent physicians that can be contacted through the Color Genomics website. It is available in about 100 countries.